Insight Molecular Diagnostics Inc IMDX
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2015-12-30 |
| Shares Out. | 32,290,000 |
| Website | imdxinc.com/ ↗ |
| Phone | 19494097600 |
| Employees | 58 |
| Revenue | $32,000 |
| Gross Profit | $15,000 |
| Net Income | -$4.3M |
| Free Cash Flow | -$27.5M |
| Total Assets | $40.4M |
| Total Liabilities | $51.1M |
| Equity | -$10.7M |
About Insight Molecular Diagnostics Inc
Insight Molecular Diagnostics Inc is a pioneering diagnostics technology company whose mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes. The Company's flagship technology quantifies a molecular biomarker known as donor-derived cell-free DNA (dd-cfDNA). It is also in the process of rebranding its RUO test kit, GraftAssure, as GraftAssureIQ, and rebranding its future in-vitro diagnostic (IVD) test kit as GraftAssureDx. The company geographically operates in the United States, the United Kingdom, Europe, and the Asia-Pacific regions, with maximum revenue generated from the USA.
Insight Molecular Diagnostics Inc is a publicly traded company under the ticker symbol IMDX on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
10 analysts (2026-07-01)